Linked Life Data

14623538

Source:http://linkedlifedata.com/resource/pubmed/id/14623538

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3-5
pubmed:dateCreated
2003-11-19
pubmed:abstractText
The use of hormonal therapies for the treatment of breast cancer is common, yet few studies have examined the possible cognitive effects. Several regions of the brain, important in memory and cognition, are rich in oestrogen receptors. As a result, the long-term use of anti-oestrogens may have potential consequences for cognition. This project aims to establish whether significant cognitive deficit exists in women receiving hormone therapy for breast cancer and to develop a cognitive package that is sensitive to the potential effects of oestrogen deficiency on cognition. Cognitive assessments measured a range of memory and attention functions in patient and control groups to identify whether cognitive impairment, if apparent, occurs at a widespread or function specific level. Ninety-four patients from the anastrozole, tamoxifen and combined (ATAC) trial and 35 non-cancer controls were assessed. Groups did not differ significantly in age or estimated full-scale intelligence. The patient group did not differ from controls on measures of working memory, attention and visual memory but was significantly impaired compared to the control group on measures of verbal memory (P=0.026) and processing speed (P=0.032). Cognitive performance in the patient group was not significantly related to length of time on trial or measures of psychological morbidity. As more and more hormonal agents are used in clinical trials of both adjuvant and preventive settings it is of vital importance that any potentially deleterious effects on cognitive function are measured adequately. Preliminary results from this study suggest that anti-oestrogen therapy may cause a specific deficit in verbal memory that corroborates the links between oestrogen levels and verbal memory often reported in studies of the cognitive benefits of hormone replacement therapy.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0960-0760
pubmed:author
pubmed:issnType
Print
pubmed:volume
86
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
405-12
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:14623538-Affect, pubmed-meshheading:14623538-Aged, pubmed-meshheading:14623538-Aged, 80 and over, pubmed-meshheading:14623538-Antineoplastic Agents, Hormonal, pubmed-meshheading:14623538-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:14623538-Breast Neoplasms, pubmed-meshheading:14623538-Cognition, pubmed-meshheading:14623538-Cognition Disorders, pubmed-meshheading:14623538-Enzyme Inhibitors, pubmed-meshheading:14623538-Female, pubmed-meshheading:14623538-Humans, pubmed-meshheading:14623538-Memory, pubmed-meshheading:14623538-Middle Aged, pubmed-meshheading:14623538-Nitriles, pubmed-meshheading:14623538-Pilot Projects, pubmed-meshheading:14623538-Psychometrics, pubmed-meshheading:14623538-Randomized Controlled Trials as Topic, pubmed-meshheading:14623538-Tamoxifen, pubmed-meshheading:14623538-Triazoles
pubmed:year
2003
pubmed:articleTitle
The effects of hormone therapy on cognition in breast cancer.
pubmed:affiliation
Psychosocial Oncology Group (Cancer Research UK), Brighton and Sussex Medical School, University of Sussex, Falmer, East Sussex, BN1 9QG, UK. v.shilling@biols.susx.ac.uk
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't